Discrepancies in Genetic Testing Procedures of BRCA1/2 Mutations: A National Survey Across China (vol 24, pg 715, 2020)

Huanwen Wu,Binghe Xu,Qinglei Gao,Xiaoyan Zhou,Jianyong Shao,Zhiyong Liang,Ding Ma

DOI: https://doi.org/10.1007/s40291-021-00512-y

2021-01-01

Molecular Diagnosis & Therapy

Abstract:In the original publication of the article, text in Table 1 has a few errors as mentioned below.

What problem does this paper attempt to address?

Prevalence and Reclassification of BRCA1 and BRCA2 Variants in a Large, Unselected Chinese Han Breast Cancer Cohort

Yun Liu,Honglian Wang,Jiaqi Liu,Junjian Li,Xin Wang,Xiang Wang,Yun Zhang,Zhigang Bai,Qinghua Zhou,Ying Wu,Yi Shen,Xiaoling Weng,Fatao Liu,Jiancheng Guo,Olivier Gires,Zhong-tao Zhang,Yiding Chen,Hongxia Wang

DOI: https://doi.org/10.2139/ssrn.3463315

2019-01-01

SSRN Electronic Journal

Abstract:Background: Accurate interpretation of BRCA1/2 variants is critical for risk assessment, enhanced cancer surveillance, prevention strategies, and precise clinical treatment of breast cancer. However, current worldwide standards depend primarily on sequencing information from Caucasian populations.Methods: Panel-based sequencing served to detect BRCA1/2 variants in a Chinese multicenter cohort of 21,216 breast cancer patients (BCs) and 6,434 healthy controls (HCs).Findings: 1,245 pathogenic variants of BRCA1/2, 262 of which were novel (21.04%), and 2,517 variants of uncertain significance (VUS) were identified. Unlike in the Caucasian population, BRCA2 variants were more frequent than BRCA1 variants (56.34% versus 43.66%). The 48 most common variants accounted for 39.86% of all pathogenic variants, and were not reported as common variants in Caucasians. Furthermore, we unambiguously reclassified VUS in 508 subjects, lowering the VUS ratio from 9.05% to 7.21%. Pathogenic BRCA1/2 variants correlated with younger onset age, higher frequencies of bilateral and triple-negative BC, invasive carcinomas, high histological grades, and family history of BC and other cancers.Interpretation: Strong ethnicity-specific occurrences of pathogenic BRCA1/2 variants were identified in the Chinese population. Hence, the findings provide rationale and sequencing information for the implementation of BRCA1/2 variants tailored to the Chinese population into clinical risk assessment.Funding Statement: National Natural Science Foundation of China 81772802, Shanghai science and technology innovation action plan of China 17JC1404400 and 16DZ19102, Special Funds for Technological Innovation of Shanghai Jiao Tong University YG2016MS22, Chinese Academy of Science XDA12020223 (W.H.X), Natural Science Foundation of Zhejiang Province LZ16H160002 (C.Y.D), Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents (C.Y.D).Declaration of Interests: Authors declare no potential conflicts of interest.Ethics Approval Statement: The study was approved by the Ethics Committee of all the hospitals involved and was performed according to the Declaration of Helsinki Principles. Written consent to notify blood samples for future research was obtained for each patient under the Institutional Review Board (IRB)-approved protocol.
Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients (vol 11, 655709, 2021)

Jun Li,Sile Han,Cuiyun Zhang,Yanlin Luo,Li Wang,Ping Wang,Yi Wang,Qingxin Xia,Xiaoyan Wang,Bing Wei,Jie Ma,Hongle Li,Yongjun Guo

DOI: https://doi.org/10.3389/fonc.2021.840551

IF: 4.7

2022-01-01

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.655709.].
[Analysis of the Mutations of BRCA1 in 9 Familiar Breast Cancer Patients].

Shanming Deng,Yi Wang,Yang Ke,Guangwei Xu

DOI: https://doi.org/10.3969/j.issn.1000-9760.2011.02.007

2003-01-01

Abstract:OBJECTIVETo analyze the mutations of BRCA1 in 9 Chinese familiar breast cancer patients.METHODSPeripheral blood samples were obtained from 9 patients enrolled from 9 breast cancer families, one normal control, 32 sporadic breast cancer patients and 33 normal donors. DNA extracted from lymphocytes was amplified by polymerase chain reaction (PCR). The 22 exons and partial introns of BRCA1 were screened by PCR-denaturing high performance liquid chromatography (PCR-DHPLC) and confirmed by direct sequencing.RESULTSAmong these 9 familiar breast cancer patients, a deleterious mutation was detected in one case in exon 11 (3870delTGTC) which was a 4-base deletion and caused a frameshift in turn. One novel and unique amino acid substitution (E867R) was detected in one case. Eight patients were detected to have a known variation in intron 18 (IVS18 + 65G-->A), and the ratio of this variation detected was 88.9% (8/9). The ratio of this variation was 37.5% (12/32) in sporadic breast cancer patients or 33.3% (11/33) in normal control. This variation was found to be accompanied all the time with a known missense variation in exon 11 (P871L) and a polymorphism in intron 9 (IVS8-57delT). Those three variants were also detected in homozygous in one case, which implies the linkage of the 3 sites. The linkage had not been reported. Two patients had been found with a known polymorphism in exon 13 (S1436S). Another known polymorphism was found in one case (L771L). In addition, intronic variants (IVS2 + 48C-->T, IVS2 + 133C-->T, IVS12 + 112C-->A) were detected.CONCLUSIONThe mutations of BRCA1 in Chinese familiar breast cancer patients are different from the hot spots reported in Caucasian and Jewish. It is important that further study be conducted to seek for specific mutations of this gene or other possible relevant genes in Chinese familiar breast cancer patients.
Corrigendum to “from Phenotype to Gene: Detecting Disease‐specific Gene Functional Modules Via a Text‐based Human Disease Phenotype Network Construction” [FEBS Lett. 584 (2010) 3635–3643]

Shihua Zhang,Chao Wu,Xia Li,Xi Chen,Wei Jiang,Binsheng Gong,Li Jiang,Yuqing Yan

DOI: https://doi.org/10.1016/j.febslet.2012.12.013

2012-01-01

FEBS Letters

Abstract:The name of the first author was misspelled. The correct name should read: Shihua Zhang.
Correction: Corrigendum: Identification of novel PKD1 and PKD2 mutations in a Chinese population with autosomal dominant polycystic kidney disease

Liu, Bei,Chen, Song-Chang,Yang, Yan-Mei,Yan, Kai,Qian, Ye-Qing,Zhang, Jun-Yu,Hu, Yu-Ting,Dong, Min-Yue,Jin, Fan,Huang, He-Feng,Xu, Chen-Ming

DOI: https://doi.org/10.1038/srep21578

IF: 4.6

2016-01-01

Scientific Reports

Abstract:Scientific Reports 5: Article number: 17468; published online: 03 December 2015; updated: 23 February 2016 This Article contains typographical errors in Table 2. For Family No. 19, the cDNA change ‘c.8795_8796insA’ and protein change ‘p.His2932GlnfsX5’ were incorrectly given as ‘c.8495-8496insA’ and‘p.
Correction To: Early Presence of Anti-Angiogenesis-related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Metastatic Gastric Cancer Patients Treated with Apatinib: a Cohort Study

Xinyang Liu,Shukui Qin,Zhichao Wang,Jianming Xu,Jianping Xiong,Yuxian Bai,Zhehai Wang,Yan Yang,Guoping Sun,Liwei Wang,Leizhen Zheng,Nong Xu,Ying Cheng,Weijian Guo,Hao Yu,Tianshu Liu,Pagona Lagiou,Jin Li

DOI: https://doi.org/10.1186/s13045-017-0545-5

IF: 28.5

2017-01-01

Journal of Hematology & Oncology

Abstract:The original article [1] contains two errors in Table 2
Author Correction: BHMT Polymorphism and Susceptibility to PTE in Chinese Patients.

W-H Zhang,S-M Zhao,J-F Guo,Y-P Liu,Y-Q Jiang

DOI: https://doi.org/10.26355/eurrev_202307_32944

2023-01-01

European review for medical and pharmacological sciences

Abstract:Correction to: Eur Rev Med Pharmacol Sci 2023; 27 (9): 4098-4102. DOI: 10.26355/eurrev_202305_32317-PMID: 37203835-published online on May 15, 2023. After publication, the authors applied a correction in the Funding section. The section has been amended as follows: This study was supported by the research program of Jilin Provincial Science and Technology Department (No. 20190201011J). There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/32317.
The analysis of BRCA1 mutations in eastern Chinese patients with early onset breast cancer and affected relatives.

Zhen Hu,Jiong Wu,Can-Hui Liu,Jing-Song Lu,Jian-Ming Luo,Qi-Xia Han,Zhen-Zhou Shen,Zhi-Ming Shao

DOI: https://doi.org/10.1002/humu.9156

2003-01-01

Human Mutation

Abstract:To study the BRCA1 mutations in eastern Chinese patients with early onset breast cancer and affected relatives, 41 patients' genomic DNA from peripheral mononuclear blood cells was studied by using single strand conformational polymorphism (SSCP) and DNA sequencing. The BRCA1 mutations were detected in the whole gene sequence. Three novel disease-causing mutations (c.582C>T, c.735C>T and c.2790delT) occurred in all the patients. Two occurred in the patients younger than 35 years old (9.1%) and one in the patients with affected relatives (5%). Additional sequence variants identified included a novel missense mutation of unknown significance and six polymorphisms. The prevalence of BRCA1 mutations in Chinese patients in Shanghai with early onset breast cancer is similar to that observed in western women, but the incidence of mutations in breast cancer patients in Shanghai with affected relatives isn't as high as that in western women.
Errors in Key Points and Abstract

DOI: https://doi.org/10.1001/jamaoncol.2024.0267

IF: 33.006

2024-03-23

JAMA Oncology

Abstract:In the Original Investigation titled "Investigation of Genetic Alterations Associated With Interval Breast Cancer," 1 published online January 25, 2024, there were errors in the Key Points and In the Key Points, "health controls" now correctly reads "healthy controls." In the , the phrase "and associated with BRCA1/2 and PALB2 variants" is now the sentence "This association was primarily influenced by BRCA1/2 and PALB2 variants." This article was corrected online.

oncology
Corrigendum: Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients

Jun Li,Sile Han,Cuiyun Zhang,Yanlin Luo,Li Wang,Ping Wang,Yi Wang,Qingxin Xia,Xiaoyan Wang,Bing Wei,Jie Ma,Hongle Li,Yongjun Guo

DOI: https://doi.org/10.3389/fonc.2021.840551

IF: 4.7

2022-01-14

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.655709.].

oncology
Analysis of BRCA1 Mutations in Chinese Patients with Early Onset Breast Cancer and Affected Relatives

Zhen Hu,Jiong Wu,Jin-song Lu,Jian-min Luo,Qi-xia Han,Zhen-zhou Shen,Zhi-min Shao

DOI: https://doi.org/10.3760/j.issn:0253-3766.2004.11.005

2004-01-01

Abstract:OBJECTIVE:To study the BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives.METHODS:Genomic DNA from 41 patients' peripheral blood mononuclear cells was studied by using polymerase chain reaction-single strand conformational polymorphism (PCR-SSCP) and DNA sequencing. BRCA1 mutations were detected in the whole gene sequence.RESULTS:Disease-related BRCA1 mutations were detected in 3 of the 41 patients studied. Two of the 3 patients were younger than 35 years old, and one patient with family history.CONCLUSION:The incidence of BRCA1 mutations in Chinese patients with early onset breast cancer is similar to that reported from western countries, but the incidence of mutations in Chinese breast cancer patients with affected relatives is comparatively low.
BRCA1 and BRCA2 Gene Mutations of Familial Breast Cancer from Shanghai in China

Chuan-gui Song,Zhen Hu,Wen-tao Yuan,Gen-hong Di,Zhen-zhou Shen,Wei Huang,Zhi-min Shao

DOI: https://doi.org/10.3760/j.issn:1003-9406.2006.01.007

2006-01-01

Abstract:OBJECTIVE:To investigate the prevalence of BRCA1 and BRCA2 gene mutations among breast cancer patients with affected relatives in Shanghai of China.METHODS:Thirty-five breast cancer patients who had at least one first-degree relative affected were analyzed, among whom 13 patients suffered from breast cancer at age of less than 40 years. A comprehensive BRCA1 and BRCA2 mutation analysis was performed through denaturing high-performance liquid chromatography (DHPLC) and subsequent DNA direct sequencing.RESULTS:Four mutations in BRCA1 gene, including 2 novel splice-site mutations (IVS17-1G>T, IVS21+1G>C) and 2 frameshift mutations (1100delAT; 5640delA) were identified. One frameshift mutation (5802delAATT) was detected in exon 11 of BRCA2. Additional 12 novel single nucleotide polymorphisms(SNPs) were detected, including a novel unclassified variant and 7 novel intronic variants in BRCA1, and 4 novel intronic variants in BRCA2, with which all caused no alteration of amino acid coding. The mutation frequency of BRCA1 and BRCA2 in patients with family history was 11.4% and 2.9%, respectively.CONCLUSION:Two novel mutations in BRCA1 may be mutations characterized to familial breast cancer of Chinese Shanghai population. The BRCA2 may contribute to mutation less than BRCA1 in familial breast cancer. Our data contribute to information on mutation spectrum of BRCA gene in Chinese population and also offer a recommended screening mode for clinical genetic testing policy in China.
Prevalence and Characterization of BRCA1 and BRCA2 Germline Mutations in Chinese Women with Familial Breast Cancer

Juan Zhang,Renguang Pei,Zhiyuan Pang,Tao Ouyang,Jinfeng Li,Tianfeng Wang,Zhaoqing Fan,Tie Fan,Benyao Lin,Yuntao Xie

DOI: https://doi.org/10.1007/s10549-011-1596-x

2011-01-01

Breast Cancer Research and Treatment

Abstract:Although there are some studies to investigate germline mutations in BRCA1/2 genes in Chinese women with familial breast cancer, many of them suffer relatively small sample size. In this study, we screened germline mutations in BRCA1/2 genes in a cohort of 409 Chinese women with familial breast cancer from north China by using a PCR-sequencing assay. A total of 43 deleterious mutations in BRCA1/2 genes were identified in this cohort, including 17 novel mutations and 6 recurrent mutations. The frequencies of BRCA1 and BRCA2 mutations were 3.9% (16/409) and 6.6% (27/409), respectively; the mutation rate of BRCA2 was 1.7-fold higher than that of BRCA1. The entire mutation rate of BRCA1/2 was 10.5% in this cohort; however, the mutation rate of BRCA1/2 genes was 23.0% in 78 familial breast cancer patients whose tumors were diagnosed at or before the age of 40. The mean age at diagnosis of breast cancer in BRCA1 carriers (42.8 years) and BRCA2 carriers (45.1 years) was younger than non-carriers (51.0 years) in this cohort (P = 0.005; P = 0.01, respectively). In addition, both BRCA1 carriers and BRCA2 carriers were more likely to exhibit triple-negative breast cancer (ER-, PgR-, and HER2-) than non-carriers (BRCA1 carriers vs. non-carriers, 69.2 vs. 23.0%, P = 0.001; BRCA2 carriers vs. non-carriers, 45.8 vs. 23.0%, P = 0.01). Our study suggested that the spectrum and characteristics of BRCA1/2 mutations in Chinese familial breast cancer exhibit some unique features, and Chinese women with familial breast cancer whose tumors are diagnosed at or before the age of 40 are good candidates for BRCA1/2 testing.
[BRCA1/2 Gene Mutation in Chinese Familial Breast Cancer Patients: a Multi-Center Report of 115 Cases].

Zhen Hu,Wen-Feng Li,Xiao-Yi Liu,Bin Zhang,Ming-Zhi Cao,Yong-Sheng Wang,Lin Zhao,Chuan-Gui Song,Jin-Song Lu,Jiong Wu,Gen-Hong DI,Kun-Wei Shen,Qi-Xia Han,Zhen-Zhou Shen,Wei Huang,Zhi-Min Shao

DOI: https://doi.org/10.3321/j.issn:0376-2491.2008.34.003

2008-01-01

Abstract:OBJECTIVE:To study the BRCA1/2 gene mutation frequency and characteristics in Chinese familial breast cancer patients.METHODS:Denaturing high-performance liquid chromatography (DHPLC) and following DNA sequencing in BRCA1/2 gene whole coding region and exon-intron splicing sites were performed in the specimens obtained during operation from 115 probands of familial breast cancer from 4 breast cancer centers in China.RESULTS:Fourteen cases of gene mutation (11 in BRCA1 and 3 in BRCA2) were found in the 115 breast cancer specimens with an overall mutation rate of 12.2%. After stratification with number of breast cancer patients in family, the frequency of mutation did not change significantly. The average age of disease onset of the families carrying BRCA1/2 mutations was significantly younger than that of the families without mutations (P < 0.01), and the higher the number of young patients in family, the higher the mutation rate.CONCLUSION:In Chinese familial breast cancer patients, age of disease-onset is an effective predictive factor of BRCA1/2 mutation, however, the predictive effect of the number of affective relatives in family is not good.
[Mutational Analysis of BRCA1 and BRCA2 Genes in Early-Onset Breast Cancer Patients in Shanghai].

Chuan-gui Song,Zhen Hu,Wen-tao Yuan,Gen-hong Di,Zhen-zhou Shen,Wei Huang,Zhi-min Shao

DOI: https://doi.org/10.3760/j:issn:0376-2491.2005.43.003

2005-01-01

Abstract:OBJECTIVE:To investigate the prevalence of BRCA1 and BRCA2 mutations among early-onset breast cancer patients in Shanghai.METHODS:Fifty patients unselected for family history, who were diagnosed with breast cancer before the age of 40 years were analyzed. Among them, 13 patients have at least one first-degree relative affected with breast cancer. Mutation screening of BRCA1 and BRCA2 was performed in the whole coding sequence through Denaturing High Performance Liquid Chromatography (DHPLC) and subsequent DNA direct sequencing.RESULTS:Six deleterious mutations, including 2 novel frameshift mutations (3449insA, 5587-1del8) and 2 novel splice-site mutations (IVS17-1G > T, IVS21 + 1G > C) in BRCA1 were identified. Two deleterious mutations detected in BRCA2, including one frameshift mutation (5950delCT) and one novel missense mutation (5911G > C), all occurring on exon 11 adjacently. Additional 12 novel sequence variants were also detected including one unclassified variant and 7 intronic variants in BRCA1, and 4 novel intronic variants in BRCA2, all causing no alteration of amino acid coding. The prevalence of BRCA1 and BRCA2 mutations in the patients with early-onset breast cancer was 12% and 4%, respectively.CONCLUSION:Four novel mutations in BRCA1 and one novel mutation in BRCA2 may be mutations characterized of early-onset breast cancer in Chinese population. Germline mutations in BRCA2 may contribute less than mutations in BRCA1 to early-onset breast cancer in Shanghai. These data contribute to information on spectrum of BRCA gene in Chinese population and also offer a recommended screening mode for clinical genetic testing programme in China.
The landscape of BRCA1 and BRCA2 alterations in Chinese ovarian cancer patients.

Minmin Hou,Li Sun,Xiuzhang Yu,Pengyao Du,Chuang Liu,Fanfan Meng,Yaxuan Zhang,Ling Li

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.e17565

IF: 45.3

2023-06-01

Journal of Clinical Oncology

Abstract:e17565 Background: BRCA1 and BRCA2 are tumour suppressor genes, involved in the homologous repair of double-stranded DNA breaks, located at 17q21.31 and 13q13.1, respectively. Germline BRCA1/2 mutations are identified in 13-15% of ovarian cancers (OC), while an additional 5-7% of ovarian cancers harbor somatic BRCA1/2 mutations among foreign populations. To determine the landscape of germline and somatic pathogenic BRCA1 and BRCA2 alterations in Chinese patients with ovarian cancer tested by next‐generation sequencing (NGS), with the aim of defining the best strategy to be implemented in future routine testing. Methods: 472 normal-paired samples from Chinese patients with ovarian cancers were analyzed using hybridization capture-based next generation sequencing. Somatic and germline mutations were identified including 500 genes associated with tumor development. Sequencing data were analyzed to call tumor specific single nucleotide variants (SNV), small insertions and deletions (InDels), copy number alterations (CNA) and gene fusions and rearrangements. Results: Overall, 472 ovarian cancer patients underwent somatic and/or germline NGS analysis, the BRCA1 and BRCA2 genes sequenced in this study covers all targeted coding exons and exon-intron boundaries. Among these patients, 54/472 (11.4%) patients carried BRCA( BRCA1/2) mutations. Inside, there were 43/472 (9.1%) patients occurred somatic BRCA mutations, 62.8% (27/43) of variants were in BRCA1 and 37.2% (16/43) were in BRCA2. Furthermore, 3 cases carried BRCA1 and BRCA2 somatic co-mutation, of which only 1 showed BRCA1/ BRCA2 copy number losses. In 54 OC patients who carried BRCA mutations, 10 patients occured copy number alterations, of which 6 patients showed BRCA1 copy number losses, 4 patients showed BRCA2 copy number losses, and 1 patient showed BRCA2 copy number gains. Germline BRCA variant was detected in 18/472 (3.8%) patients, 66.7% (12/18) of variants were in BRCA1 and 33.3% (6/18) were in BRCA2. Of the 12 BRCA1 germline mutations, 11 were pathogenic heterozygous mutations (c.2679_2682del; c.2101_2102del; c.5085_5086insT; c.1660G > T; c.4810C > T; c.1504_1508del; c.1465G > T; c.1480C > T; c.2110_2111del; c.4185+1G > A; c.81-2A > G), one was likely pathogenic heterozygous mutation (c.5216A > G). Of the 6 BRCA 2 germline mutations, four were pathogenic heterozygous mutations (c.5722_5723del; c.5291C > G; c.5164_5165del; c.3109C > T), one was likely pathogenic heterozygous mutation (c.869_870del), and one was uncertain significance heterozygous mutation (c.7976+3A > G). Conclusions: This study revealed the molecular features of BRCA1 and BRCA2 in Chinese ovarian cancer patients, which could help to identify therapeutic targets and personalize therapy management, leading to improved patient outcomes as predictive biomarkers or platinum-based therapy.

oncology
Correction to: Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis

Blanche P. Alter,Ana F. Best

DOI: https://doi.org/10.1007/s10549-020-05775-3

2020-07-08

Breast Cancer Research and Treatment

Abstract:In the original publication of the article, the first sentence in the abstract was published incorrectly.

oncology
Correction To: Proteogenomic Characterization and Comprehensive Integrative Genomic Analysis of Human Colorectal Cancer Liver Metastasis

Yu‐Shui Ma,Tao Huang,Xiaoming Zhong,Hongwei Zhang,Xianling Cong,Hong Xu,Gai‐Xia Lu,Fei Yu,Sheng Xue,Zhongwei Lv,Da Fu

DOI: https://doi.org/10.1186/s12943-019-1005-3

IF: 37.3

2019-01-01

Molecular Cancer

Abstract:Following publication of the original article [1], the authors reported an error in affiliation 5.
Prevalence of BRCA 1 / 2 large genomic rearrangements in Chinese women with sporadic triple-negative or familial breast cancer Running title : BRCA 1 / 2 large genomic rearrangements in Chinese women with breast cancer

Liming Su,Juan Zhang,Hua Meng,Tao Ouyang,Jinfeng Li,Tianfeng,Wang,Zhaoqing Fan,Tie Fan,Benyao Lin,Yuntao Xie

DOI: https://doi.org/10.1111/cge.13256

2018-01-01

Abstract:The prevalence of BRCA1/2 large genomic rearrangements (LGRs) and their underlying mechanisms have not been fully evaluated in Chinese women with breast cancer. In this study, we determined the prevalence of BRCA1/2 LGRs in 834 patients with familial breast cancer and 660 patients with sporadic triple-negative breast cancer who were negative for BRCA1/2 small-range mutations using the multiplex ligation-dependent probe amplification method. We found that twenty index patients (2.4%) in the familial breast cancer group carried a BRCA1 or BRCA2 LGR, and the frequencies of BRCA1 and BRCA2 LGRs were 1.6% and 0.8%, respectively. Seven index patients (1.1%) carried a BRCA1 LGR in 660 sporadic triple-negative breast cancer patients, whereas no BRCA2 LGRs were found in these patients. Among the BRCA1/2 LGRs, 48.1% (13/27) were novel, and the breakpoints of the majority of the LGRs were identified. ̈ BRCA1-mediated homologous recombination (HR) and Alu-mediated HR/non-homologous end-joining (NHEJ) accounted for 40% and 30% of the BRCA1 LGRs, respectively. Alu-mediated HR accounted for 71.4% of the BRCA2 LGRs, and the remaining one-third was generated through LINE-mediated NHEJ. Our findings suggest that both familial breast cancer patients and sporadic triple-negative breast cancer patients should be tested for BRCA1/2 LGRs. This article is protected by copyright. All rights reserved.
Population-based BRCA germline mutation screening in the Han Chinese identifies individuals at risk of BRCA mutation-related cancer: experience from a clinical diagnostic center from greater Shanghai area

Zhiyuan Wu,Qingyun Zhang,Yiting Jin,Xinju Zhang,Yanli Chen,Can Yang,Xuemei Tang,Haowen Jiang,Xiaoyi Wang,Xinli Zhou,Feng Yu,Bing Wang,Ming Guan

DOI: https://doi.org/10.1186/s12885-024-12089-w

IF: 4.638

2024-04-04

BMC Cancer

Abstract:Deleterious BRCA1 / 2 ( BRCA ) mutation raises the risk for BRCA mutation-related malignancies, including breast, ovarian, prostate, and pancreatic cancer. Germline variation of BRCA exhibits substantial ethnical diversity. However, there is limited research on the Chinese Han population, constraining the development of strategies for BRCA mutation screening in this large ethnic group.

oncology

Discrepancies in Genetic Testing Procedures of <i>BRCA1/2</i> Mutations: A National Survey Across China (vol 24, pg 715, 2020)

Prevalence and Reclassification of BRCA1 and BRCA2 Variants in a Large, Unselected Chinese Han Breast Cancer Cohort

Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients (vol <i>11</i>, <i>655709</i>, <i>2021</i>)

[Analysis of the Mutations of BRCA1 in 9 Familiar Breast Cancer Patients].

Corrigendum to “from Phenotype to Gene: Detecting Disease‐specific Gene Functional Modules Via a Text‐based Human Disease Phenotype Network Construction” [FEBS Lett. 584 (2010) 3635–3643]

Correction: Corrigendum: Identification of novel PKD1 and PKD2 mutations in a Chinese population with autosomal dominant polycystic kidney disease

Correction To: Early Presence of Anti-Angiogenesis-related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Metastatic Gastric Cancer Patients Treated with Apatinib: a Cohort Study

Author Correction: BHMT Polymorphism and Susceptibility to PTE in Chinese Patients.

The analysis of BRCA1 mutations in eastern Chinese patients with early onset breast cancer and affected relatives.

Errors in Key Points and Abstract

Corrigendum: Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients

Analysis of BRCA1 Mutations in Chinese Patients with Early Onset Breast Cancer and Affected Relatives

BRCA1 and BRCA2 Gene Mutations of Familial Breast Cancer from Shanghai in China

Prevalence and Characterization of BRCA1 and BRCA2 Germline Mutations in Chinese Women with Familial Breast Cancer

[BRCA1/2 Gene Mutation in Chinese Familial Breast Cancer Patients: a Multi-Center Report of 115 Cases].

[Mutational Analysis of BRCA1 and BRCA2 Genes in Early-Onset Breast Cancer Patients in Shanghai].

The landscape of BRCA1 and BRCA2 alterations in Chinese ovarian cancer patients.

Correction to: Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis

Correction To: Proteogenomic Characterization and Comprehensive Integrative Genomic Analysis of Human Colorectal Cancer Liver Metastasis

Prevalence of BRCA 1 / 2 large genomic rearrangements in Chinese women with sporadic triple-negative or familial breast cancer Running title : BRCA 1 / 2 large genomic rearrangements in Chinese women with breast cancer

Population-based BRCA germline mutation screening in the Han Chinese identifies individuals at risk of BRCA mutation-related cancer: experience from a clinical diagnostic center from greater Shanghai area